+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis



MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis



Cancer. 79(9): 1710-1716



BACKGROUND: The clinical Stage I of nonseminomatous germ cell tumors (NSGCT) is inaccurate in 30% of patients. In previous studies on tumor biologic risk factors, low tumor proliferation rates predicted a group of patients at low risk for occult metastatic disease. The goal of this study was to confirm the immunohistochemical assessment of tumor proliferation using MIB-1 (Ki-67 receptor) in a different patient cohort with different investigators to prove the method's reliability. METHODS: Orchiectomy specimens of 78 patients with clinical Stage I NSGCT (50 patients with pathologic Stage 1 and 28 patients with pathologic Stage II disease, all patients underwent retroperitoneal lymph node dissection) were retrospectively analyzed by histopathologic reevaluation and MIB-1 immunostaining. RESULTS: Mean MIB-1 values between the two pathologic stages differed significantly (51.5% MIB-1 positive tumors cells in pathologic Stage I and 75.1% MIB-1 positive tumor cells in pathologic Stage II disease; P = 0.02). Using a 70% cutoff value, pathologic stages were correctly classified in 69% of cases (sensitivity of 86%, specificity of 60%, negative predictive value of 88%, and positive predictive value of 55%). Compared with traditional risk factors such as percentage of embryonal carcinoma and vascular invasion, in multivariate analysis, MIB-1 was the best predict;or of patients at low risk for metastasis. CONCLUSIONS: This study in a different patient population with different investigators confirmed previous results of MIB-1 staining to predict a group of patients with clinical Stage I NSGCT who were at low risk for metastasis. The method is simple and reproducible to improve risk classification in low stage testicular carcinoma. Using this technique, a group of patients at very low risk for metastasis can be identified. (See editorial counterpoint on pages 1641-5 and reply to counterpoint on page 1646, this issue.)

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008981591

Download citation: RISBibTeXText

PMID: 9128986

DOI: 10.1002/(sici)1097-0142(19970501)79:9<1710::aid-cncr11>3.0.co;2-0


Related references

MIB-1 Immunohistochemistry in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Predicts Patients at Low Risk for Metastasis. Journal of Urology 160(6): 2291-2292, 1998

MIB-1 analysis predicts low-risk patients with clinical stage A nonseminomatous germ cell tumors. Journal of Urology 155(5 SUPPL ): 326A, 1996

Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Medical Oncology 30(1): 494, 2013

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83(5): 1002-1011, Sept 1, 1998

A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. Journal of Urology 171(1): 172-176, 2003

Flow cytometric DNA ploidy pattern for predicting metastasis of clinical stage I nonseminomatous germ cell testicular tumors. Urology 41(4): 379-383, 1993

Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. Journal of Urology 161(4): 1148-1152, 1999

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World Journal of Urology 33(9): 1351-1357, 2016

The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Seminars in Urology 11(2): 92-98, 1993

Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. Yearbook of Urology 2014: 285-286, 2014

Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. European Urology 33(6): 562-566, 1998

Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors. Journal of Urology 191(5 Suppl): 1485-1490, 2014

Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer (philadelphia). 75(3): 844-850, 1995

DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67(7): 1874-1877, 1991